

## 24<sup>th</sup> “Nantes Actualités en Transplantation” & 4<sup>th</sup> “LabEx IGO Meeting”

La Cité Nantes Congress Centre



## New horizons in immunotherapy

Organised by:



Member organisations:



In partnership with:



**Chairwoman:** Carole GUILLONNEAU – U1064 CRTI

### Scientific committee

Frédéric ALTARE - U1232 CRCINA  
Ignacio ANEGON - U1064 CRTI  
Sophie BROUARD - U1064 CRTI  
Yves DELNESTE – Cancéropôle Grand Ouest  
Jean-François FONTENEAU - U1232 CRCINA  
Nathalie LABARRIERE - U1232 CRCINA  
Jérôme MARTIN - U1064 CRTI  
Catherine RABU – U1232 CRCINA  
Mikaël ROUSSEL – U1236 MICMAC

### Local organising committee

Giancarlo ESPEJO - LabEx IGO  
Céline KERANDEL – ITUN U1064 CRTI  
Nina SKYBYK - NExT I-Site University of Nantes  
Laurence WOLFF - LabEx IGO

## Programme

## DAY 1 - THURSDAY, MAY 28<sup>TH</sup> 2020

8:00 am Registration & welcome coffee

8:45 am **Welcome Speech**  
**Carole Guillon**neau, U1064 CRTI, Nantes

### SESSION I - ADVANCED CELL THERAPY

Chairmen: Paolo Dellabona & Nathalie Labarrière

9:00 am **Reprogramming Immune Cells with CRISPR**  
**Alexander Marson**, University of California, San Francisco, USA

9:30 am **Effector CAR-T cells**  
**Stanley Riddell**, Fred Hutchinson Cancer Research Center, Seattle, USA

10:00 am **CAR-Treg in transplantation and autoimmunity**  
**Ignacio Anegón**, INSERM UMR 1064-Center for Research in Transplantation and Immunology, Labex Immunology Graft Oncology, FOCIS Center of Excellence Nantes University

10:30 am Coffee break

11:00 am **Human tolerogenic dendritic cells used in clinic to regulate immune responses through lactate synthesis**  
**Auréli**e Moreau, INSERM UMR 1064 - Center for Research in Transplantation and Immunology, University of Nantes / Nantes University Hospital, France

11:30 am **Selected communications**

12:00 am Lunch break & Poster viewing session

### SESSION II - TISSUE MICROENVIRONMENT

Chairmen: Barbara Seliger & Jérôme Martin

2:00 pm **Immunoregulation of inflammation**  
**Renato Monteiro**, Center for Research on Inflammation - INSERM U1149 & CNRS ERL8252 / Paris Diderot Faculty of Medicine

2:30 pm **Evolution of a Stromal-Immune Axis in Cancer Immunology and Immunotherapy**  
**Shannon J. Turley**, Department of Cancer Immunology, Genentech, South San Francisco, CA, USA

3:00 pm **TIGIT and its cellular and bacterial ligands: new checkpoints for cancer immune therapy**  
**Ofer Mandelboim**, Institute of Medical Research Israel-Canada (IMRIC), University of Jerusalem, Israel

3:30 pm Coffee break

4:00 pm **Myeloid cells and cancer immunotherapy**  
**Antonio Sica**, Dept of Pharmacological Sciences, University of Eastern Piedmont, Novara / Head lab. Molecular Immunology, Humanitas Clinical and Research Center, Milan, Italy

4:30 pm **Selected communications**

5:00 pm Cocktail & Poster viewing session

## DAY 2 - FRIDAY MAY 29<sup>TH</sup> 2020

8:00 am Coffee

8:30 am **Keynote speech - New immunotherapies in cancer and autoimmunity**  
**Jeff Bluestone**, UCSF and Parker Foundation, USA

### SESSION III – BIOREAGENTS

Chairmen: Hans-Dieter Volk & Carole Guillonnet

9:00 am **Harnessing Innate Immunity in Cancer Therapy**  
**Eric Vivier**, Aix Marseille University, APHM, CNRS, INSERM, CIML / Hôpital de la Timone, Marseille-Immunopole / Innate Pharma Research Laboratories, Marseille, France

9:30 am **IL-2-based strategies targeting Tregs to stimulate or dampen the immune response**  
**Eliane Piaggio**, Translational immunotherapy team U938, Institut Curie, Paris

10:00 am **Targeting Trained Immunity in Organ Transplantation**  
**Jordi Ochando**, Transplant Immunology Unit, National Center of Microbiology, Instituto de Salud Carlos III, Madrid, Spain.

10:30 am Coffee break

11:00 am **Oncolytic activity of attenuated Measles virus and the defects in the type I interferon response in cancer** - **Jean-François Fonteneau**, CRCINA (INSERM U1232), Nantes

11:30 am **Selected communications**

12:00 am Lunch break

### SESSION IV - NEW HORIZONS

Chairmen: Megan Sykes & Catherine Rabu

1:30 pm **Targeting common epithelial malignancies with TCR engineered lymphocytes specific for 'public' neoantigens** - **Christopher Klebanoff**, Memorial Sloan Kettering Cancer Center and the Parker Institute for Cancer Immunotherapy, New York, USA

2:00 pm **Genetic modifications to decrease the immunogenicity of pluripotent stem cells**  
**Ludovic Vallier**, Cambridge Stem Cell Institute, Cambridge University, UK

2:30 pm **Analysis of immune-epithelial cell interactions by Imaging Mass Cytometry**  
**Nicolas Damond**, Department of Quantitative Biomedicine, University of Zurich, Switzerland

3:00 pm Coffee break

3:30 pm **Mesenchymal stromal cell heterogeneity: implication for their clinical application**  
**Karin Tarte**, Inserm U1236, University of Rennes, CHU Rennes, France

4:00 pm **Single Cell** - **Muzlifah Haniffa**, Wellcome, Lister Institute, Newcastle Biomedical Research Centre, Institute of Cellular Medicine, Newcastle University, UK

4:30 pm **Awarding ceremony: best oral presentation, best poster**